VRS 859

Drug Profile

VRS 859

Alternative Names: Exenatide-XTEN; VRS-859

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Amunix
  • Developer Versartis
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 13 Feb 2017 VRS-859 is still in phase I trials for Type-2 diabetes mellitus
  • 15 Mar 2016 Biomarkers information updated
  • 27 Oct 2014 Amunix signs services and supply agreement with the University of Nebraska-Lincoln Biological Process Development Facility for XTEN
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top